Human Genome Sciences Confirms Stock Sales By Chairman Were Completed Last Week

Apr 25, 2001, 01:00 ET from Human Genome Sciences, Inc.

    ROCKVILLE, Md., April 25 /PRNewswire/ -- Reacting to inquiries, Human
 Genome Sciences, Inc (Nasdaq:   HGSI) today confirmed that William A. Haseltine,
 Ph.D., its Chairman and Chief Executive Officer, last week completed sales of
 HGS common stock that were disclosed as intended sales in an April 16, 2001,
 SEC Form 144 report.
     The 600,000 shares sold last week constituted approximately 7.2 percent of
 Dr. Haseltine's holdings. They were sold for tax planning and investment
 diversification purposes.  A portion of the proceeds of Dr. Haseltine's sales
 are being used to establish the William A. Haseltine Foundation For Medical
 Sciences and The Arts.  Dr. Haseltine continues to own or have options to
 purchase an aggregate of more than 7.6 million shares Human Genome Science's
 common stock.
     Human Genome Sciences is a company with the mission to treat and cure
 disease by bringing new gene-based drugs to patients.
     HGS and Human Genome Sciences are registered trademarks of Human Genome
 Sciences, Inc.  For additional information on Human Genome Sciences, Inc.,
 visit the company's web site at http://www.hgsi.com .  Copies of HGS press
 releases are also available by fax 24 hours a day at no charge by calling
 800-758-5804, ext. 121115.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X23915088
 
 

SOURCE Human Genome Sciences, Inc.
    ROCKVILLE, Md., April 25 /PRNewswire/ -- Reacting to inquiries, Human
 Genome Sciences, Inc (Nasdaq:   HGSI) today confirmed that William A. Haseltine,
 Ph.D., its Chairman and Chief Executive Officer, last week completed sales of
 HGS common stock that were disclosed as intended sales in an April 16, 2001,
 SEC Form 144 report.
     The 600,000 shares sold last week constituted approximately 7.2 percent of
 Dr. Haseltine's holdings. They were sold for tax planning and investment
 diversification purposes.  A portion of the proceeds of Dr. Haseltine's sales
 are being used to establish the William A. Haseltine Foundation For Medical
 Sciences and The Arts.  Dr. Haseltine continues to own or have options to
 purchase an aggregate of more than 7.6 million shares Human Genome Science's
 common stock.
     Human Genome Sciences is a company with the mission to treat and cure
 disease by bringing new gene-based drugs to patients.
     HGS and Human Genome Sciences are registered trademarks of Human Genome
 Sciences, Inc.  For additional information on Human Genome Sciences, Inc.,
 visit the company's web site at http://www.hgsi.com .  Copies of HGS press
 releases are also available by fax 24 hours a day at no charge by calling
 800-758-5804, ext. 121115.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X23915088
 
 SOURCE  Human Genome Sciences, Inc.